Pharmanovia – The Life Cycle Management Company
The Pharmanovia story
Founded in 2013, the Company has grown from a small family business operating solely in the UK to a global specialty pharma business, marketing more than 20 brands in over 140 markets, operating through more than 10 offices (and constantly growing) with over 250 employees.
Pharmanovia is committed to making medicines available for the benefit of patient health globally in line with the highest ethical standards. The Company focuses on late-stage activities to drive growth: developing, licensing, and acquiring niche speciality products and established brands within the company’s strategic therapeutic areas endocrinology, cardiovascular, neurology and oncology.
Within its strategic therapeutic areas, Pharmanovia acquired tried and trusted medicines and iconic brands from innovator pharma companies, is redeveloping its portfolio by using life cycle management as well as in-licensing novel complementary therapies.
Why Triton invested
Health is an area where Triton has a lot of experience. The market for pharmaceutical products enjoys stable and long-term growth which is driven by increasing healthcare spending.
Specialty pharma products have a large and recurring patient base and Pharmanovia as the life cycle management company has a successful track record of acquiring iconic, tried and trusted medicines from large cap and specialty pharma companies. Further, Pharmanovia has significant opportunities to drive growth through the development and licensing of complementary and novel therapies.
The investment in Pharmanovia is based on the attractiveness of the business model, the Company’s strong track record as preferred partner to innovator pharma companies and the partnership with the previous owner.
The transformation journey
Triton is working with Pharmanovia to grow both the business and its portfolio of existing brands through marketing and promotion, life cycle management as well as by entering new markets, and moreover, through add-on acquisitions, and in-licensing of complementary and novel therapies. Based on its successful track record and position as the life cycle management company, Triton believes Pharmanovia is well placed to further progress iconic medicines for the benefit of patient health globally.
The Pharmanovia story
Founded in 2013, the Company has grown from a small family business operating solely in the UK to a global specialty pharma business, marketing more than 20 brands in over 140 markets, operating through more than 10 offices (and constantly growing) with over 250 employees.
Pharmanovia is committed to making medicines available for the benefit of patient health globally in line with the highest ethical standards. The Company focuses on late-stage activities to drive growth: developing, licensing, and acquiring niche speciality products and established brands within the company’s strategic therapeutic areas endocrinology, cardiovascular, neurology and oncology.
Within its strategic therapeutic areas, Pharmanovia acquired tried and trusted medicines and iconic brands from innovator pharma companies, is redeveloping its portfolio by using life cycle management as well as in-licensing novel complementary therapies.
Why Triton invested
Health is an area where Triton has a lot of experience. The market for pharmaceutical products enjoys stable and long-term growth which is driven by increasing healthcare spending.
Specialty pharma products have a large and recurring patient base and Pharmanovia as the life cycle management company has a successful track record of acquiring iconic, tried and trusted medicines from large cap and specialty pharma companies. Further, Pharmanovia has significant opportunities to drive growth through the development and licensing of complementary and novel therapies.
The investment in Pharmanovia is based on the attractiveness of the business model, the Company’s strong track record as preferred partner to innovator pharma companies and the partnership with the previous owner.
The transformation journey
Triton is working with Pharmanovia to grow both the business and its portfolio of existing brands through marketing and promotion, life cycle management as well as by entering new markets, and moreover, through add-on acquisitions, and in-licensing of complementary and novel therapies. Based on its successful track record and position as the life cycle management company, Triton believes Pharmanovia is well placed to further progress iconic medicines for the benefit of patient health globally.
Location: United Kingdom, England, Basildon
Investors 1
| Date | Name | Website |
| 02.05.2023 | Triton | triton-par... |
Mentions in press and media 6
| Date | Title | Description |
| 31.07.2026 | IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand | SHANGHAI, July 31, 2026 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT") (07630.HK) is pleased to announce that it has entered into an exclusive partnership (the "Exclusive Partnership") with Pharmanovia, a global specialt... |
| 03.02.2025 | Lindus Health: ‘Anti-CRO’ Company Raises $55 Million (Series B) | Lindus Health, an the anti-CRO running faster and more reliable clinical trials, announced it has raised $55 million in Series B funding. This funding round was led by new investor Balderton Capital, with support from Visionaries Club and e... |
| 22.01.2025 | Lindus Health Raises $55M to Accelerate AI-Driven Clinical Trials | What You Should Know: – Lindus Health, a company transforming the clinical trial landscape with its tech-first approach raises $55M in Series B funding round led by Balderton Capital, with participation from Visionaries Club and existing in... |
| 18.10.2024 | OncoZenge AB intends to enter partnership with Pharmanovia for commercialization of BupiZenge™ in Europe, Middle East & North Africa | OncoZenge AB intends to enter partnership with Pharmanovia for commercialization of BupiZenge™ in Europe, Middle East & North Africa Fri, Oct 18, 2024 10:00 CET Report this content STOCKHOLM, SWEDEN – October 18, 2024 – OncoZenge AB (pu... |
| 01.06.2023 | Lindus Health kicks off more clinical trials through its clinical trial management platform | London-based medtech Lindus Health has announced a new rake of clinical trials which will be managed through its platform. It claims that using its clinical trial management platform it can speed trials up to three times faster than the tra... |
| 20.07.2021 | Pharmanovia expands strategic collaboration with M8 Pharmaceuticals in Latin America |